Myeloid-derived suppressor cells and tolerogenic dendritic cells are distinctively induced by PI3K and Wnt signaling pathways

Imbalanced immune responses are a prominent hallmark of cancer and autoimmunity. Overactive as well as suppressed immunological activity is evidenced to promote disease. This immunological disbalance is often driven through disrupted immunomodulation by innate myeloid immune cells. Myeloid cells can...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of biological chemistry 2023-11, Vol.299 (11), p.105276-105276, Article 105276
Main Authors: van Wigcheren, Glenn F., Cuenca-Escalona, Jorge, Stelloo, Suzan, Brake, Julia, Peeters, Eline, Horrevorts, Sophie.K., Frölich, Siebren, Ramos-Tomillero, Iván, Wesseling-Rozendaal, Yvonne, van Herpen, Carla M.L., van de Stolpe, Anja, Vermeulen, Michiel, de Vries, I. Jolanda M., Figdor, Carl G., Flórez-Grau, Georgina
Format: Article
Language:English
Subjects:
Dendritic Cells - immunology
Humans
immune tolerance
Immunomodulation - immunology
immunosuppression
Immunotherapy
MDSC
Myeloid-Derived Suppressor Cells - immunology
Neoplasms - immunology
Neoplasms - therapy
Phosphatidylinositol 3-Kinases - immunology
Proto-Oncogene Proteins c-akt - immunology
Signal Transduction - immunology
TolDC
Tumor Cells, Cultured
Wnt Signaling Pathway - immunology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Imbalanced immune responses are a prominent hallmark of cancer and autoimmunity. Overactive as well as suppressed immunological activity is evidenced to promote disease. This immunological disbalance is often driven through disrupted immunomodulation by innate myeloid immune cells. Myeloid cells can be overly suppressive, inhibiting protective immune responses or be inactive not controlling autoreactive immune cells. Understanding the mechanisms that induce and drive suppressive myeloid cells, such as myeloid-derived suppressor cells (MDSCs) and tolerogenic dendritic cells (TolDCs), can facilitate the development of immune-restoring therapeutic approaches in patients. MDSCs are a major barrier for effective cancer immunotherapy by suppressing antitumor immune responses in cancer patients. TolDCs are administered to patients to promote immune tolerance with the intent to control autoimmune disease. Here, we investigated the development and suppressive/tolerogenic activity of human MDSCs and TolDCs derived from monocytes to gain insight into signaling pathways that drive immunosuppression in these different myeloid subsets. Moreover, human monocyte-derived MDSCs (M-MDSCs) generated in vitro were compared to M-MDSCs isolated from head-and-neck squamous cell carcinoma patients. PI3K-AKT signaling was identified as being crucial for the induction of human M-MDSCs. PI3K inhibition prevented the downregulation of HLA-DR, the upregulation of reactive oxygen species and MerTK, and subsequent suppressive activity of M-MDSCs towards T cells. In addition, we show for the first time that the suppressive activity of dexamethasone-induced TolDCs is induced by β-catenin–dependent Wnt signaling. The identification of PI3K-AKT and Wnt signal transduction pathways as respective inducers of the immunomodulatory capacity of M-MDSCs and TolDCs provides opportunities to overcome suppressive myeloid cells in cancer patients and optimize therapeutic application of TolDCs in patients with autoimmune diseases. Lastly, the observed similarities between generated- and patient-derived M-MDSCs support the use of in vitro–generated M-MDSCs as powerful model to investigate the functionality of human MDSCs.
ISSN:0021-9258
1083-351X
DOI:10.1016/j.jbc.2023.105276